티볼론과 에스트라디올 기반 호르몬 치료가 골밀도와 혈중 지질에 미치는 영향
The Effect of Tibolone and Estradiol-based Hormone Therapy on Bone Mineral Density and Serum Lipid Profiles
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: To investigate the differences between the effect of tibolone and estradiol (E2)-based hormone therapy (HT) on bone mineral density (BMD) and serum lipid profiles in postmenopausal Korean women. Materials and Methods: A retrospective study was conducted with 65 postmenopausal women receiving tibolone or E2-based hormone therapy in university hospital. BMD at lumbar spine (LS) and proximal femur was measured before and after 1 year of therapy and serum total cholesterol, triglyceride (TG) and high-density lipoprotein (HDL) was determined by enzymatic methods. Results: BMD at LS increased after 1 year of tibolone (mean change: 3.0%) or E2-based HT (mean change: 1.6%), and the changes were significant (P=0.002 and 0.04, respectively). In E2 group, serum total cholesterol has decreased significantly after 1 year of therapy (P=0.02). Moreover, the change of HDL level was statistically significant in tibolone group compared to E2 group (P=0.01). The changes of levels of total cholesterol, TG and HDL has demonstrated negative relationship of BMD changes at femur neck and trochanter in tibolone group, whereas only the HDL changes were significantly related to the change of trochanter BMD in E2 group. Conclusions: Both tibolone and E2-based hormone therapy increased BMD at lumbar spine. The changes of serum lipid levels may be associated with the BMD changes in both groups although the relationships were different according to the regimen.
Abstract
Objectives: To investigate the differences between the effect of tibolone and estradiol (E2)-based hormone therapy (HT) on bone mineral density (BMD) and serum lipid profiles in postmenopausal Korean women. Materials and Methods: A retrospective study was conducted with 65 postmenopausal women receiving tibolone or E2-based hormone therapy in university hospital. BMD at lumbar spine (LS) and proximal femur was measured before and after 1 year of therapy and serum total cholesterol, triglyceride (TG) and high-density lipoprotein (HDL) was determined by enzymatic methods. Results: BMD at LS increased after 1 year of tibolone (mean change: 3.0%) or E2-based HT (mean change: 1.6%), and the changes were significant (P=0.002 and 0.04, respectively). In E2 group, serum total cholesterol has decreased significantly after 1 year of therapy (P=0.02). Moreover, the change of HDL level was statistically significant in tibolone group compared to E2 group (P=0.01). The changes of levels of total cholesterol, TG and HDL has demonstrated negative relationship of BMD changes at femur neck and trochanter in tibolone group, whereas only the HDL changes were significantly related to the change of trochanter BMD in E2 group. Conclusions: Both tibolone and E2-based hormone therapy increased BMD at lumbar spine. The changes of serum lipid levels may be associated with the BMD changes in both groups although the relationships were different according to the regimen.
참고문헌 (30)
- Korean National Statistical Office, "Statistics on the aged", ~ (2006)
- Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
- Wood CE, "Comparative effects of oral conjugated equine estrogens and micronized 17betaestradiol on breast proliferation: a retrospective analysis", Menopause, 15, pp.890~898 (2008)
- Sneader W., "The discovery of oestrogenic hormones", Menopause Int, 6, pp.129~133 (2000)
- Gräser T, "Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints", Climacteric, 4, pp.332~342 (2001)
- Heikkinen J, "A 10-year follow-up of the effect of continuouscombined hormone replacement therapy and its discontinuation on bone in postmenopausal women", Menopause Int, 14, pp.70~77 (2008)
- Cummings SR, "The effects of tibolone in older postmenopausal women", N Engl J Med, 359, pp.697~708 (2008)
- Ederveen AG, "Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor", J Bone Miner Res, 16, pp.1651~1657 (2001)
- Berning B, "Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study", Bone, 19, pp.395~399 (1996)
- Gallagher JC, "Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies", J Clin Endocrinol Metab, 86, pp.4717~4726 (2001)
- Lippuner K, "Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone", J Bone Miner Res, 12, pp.806~812 (1997)
- Rymer J, "Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss", Osteoporos Int, 12, pp.478~483 (2001)
- Castelo-Branco C, "Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women", Maturitas, 34, pp.161~168 (2000)
- Adami S, "Relationship between lipids and bone mass in 2 cohorts of healthy women and men", Calcif Tissue Int, 74, pp.136~142 (2004)
- Cui LH, "Association between bone mineral densities and serum lipid profiles of preand post-menopausal rural women in South Korea", Osteoporos Int, 16, pp.1975~1981 (2005)
- Meier CR, "Statin drugs and the risk of fracture", JAMA, 284, pp.1921~1922 (2000)
- Wang PS, "HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients", JAMA, 283, pp.3211~3216 (2000)
- 박진완, "지질대사에 관한 지속적 병합 호르몬 요법과 티볼론 요법의 비교연구", Obstetrics & Gynecology Science, 45(4), pp.19~19 (2002), 대한산부인과학회
- Yang SH, "Effects of tibolone on postmenopausal osteoporosis, lipid, mammograph compared with continuous combined hormone replacement therapy", J Korean Acad Fam Med, 22, pp.904~914 (2001)
- Namkung J, "Comparison of the Effects of Hormone Replacement Therapy on Bone Mineral Density, Lipid Profiles, and Biochemical Markers of Bone Metabolism", J Korean Soc Menopause, 16, pp.107~115 (2010)
- Heiss G, "Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin", JAMA, 299, pp.1036~1045 (2008)
- Kloosterboer HJ, "Tibolone: a steroid with a tissuespecific mode of action", J Steroid Biochem Mol Biol, 76, pp.231~238 (2001)
- Archer DF, "Endometrial effects of tibolone", J Clin Endocrinol Metab, 92, pp.911~918 (2007)
- Markiewicz L, "In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium", J Steroid Biochem, 35, pp.535~541 (1990)
- Johnston CC Jr, "Early menopausal changes in bone mass and sex steroids", J Clin Endocrinol Metab, 61, pp.905~911 (1985)
- Cummings SR, "Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group", JAMA, 283, pp.1318~1321 (2000)
- von Eckardstein A, "High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport", Arterioscler Thromb Vasc Biol, 21, pp.13~27 (2001)
- Friedewald WT, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge", Clin Chem, 18, pp.499~502 (1972)
- Bots ML, "The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study", Eur Heart J, 27, pp.746~755 (2006)
- Park JW, "The Effect of Tibolone on Bone Mineral Density in Postmenopausal Women with Osteopenia or Osteoporosis", Korean J Obstet Gynecol, 42, pp.1324~1327 (1999)